In Depth Research on Global Cancer Biosimilars Market Opportunity Outlook

"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:

* Introduction & Mechanism of Cancer Biosimilars
* Global Cancer Biosimilars Market Dynamics
* FDA & EMA Guidelines on Development & Marketing of Biosimilars
* Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
* Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
* Marketed Cancer Biosimilars Clinical Insight
* Marketed Cancer Biosimilars: 15 Biosimilars

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Cancer-Biosimilars-Market-Opportunity-Outlook.php

Table of Contents

1. Introduction to Cancer Biosimilars

2. Mechanism of Cancer Biosimilars

3. Considerations While Marketing Cancer Biosimilars in Global Market

4. EU & US Regulatory Considerations on Cancer Biosimilars

5. Global Cancer Biosimilars Market Overview
5.1 Current Market Scenario
5.2 Cancer Biosimilars Pipeline Overview

6. Global Cancer Biosimilars Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Global Cancer Biosimilars Market Future Prospects

8. EMA Guidelines on Development & Marketing of Biosimilars
8.1 Development of Similar Biological Medicinal Products Containing r-hFSH
8.2 Similar Biological Medicinal Products Containing Interferon Beta
8.3 Immunogenicity Assessment of Monoclonal Antibodies Intended For In Vivo Clinical Use
8.4 Similar Biological Medicinal Products Containing Monoclonal Antibodies
8.5 Similar Biological Medicinal Products Containing Recombinant Erythropoietins
8.6 Similar Medicinal Products Containing Recombinant Human Soluble Insulin
8.7 Similar Medicinal Products Containing Somatropin
8.8 Similar Biological Medicinal Products Containing Biotechnology Derived Proteins as Active Substance
8.9 Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins
8.10 Comparability of Biotechnology-Derived Medicinal Products After A Change In The Manufacturing Process

9. FDA Guidelines on Development & Marketing of Biosimilars
9.1 Quality Considerations In Demonstrating Biosimilarity To A Reference Protein Product
9.2 Scientific Considerations In Demonstrating Biosimilarity To A Reference Product

10. Regulatory Pathways for Development & Marketing of Biosimilars by Country
10.1 Australia
10.2 Canada
10.3 Japan
10.4 India
10.5 Malaysia
10.6 Saudi Arabia
10.7 Singapore
10.8 South Africa
10.9 South Korea
10.10 Turkey

11. Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-III
11.9 Registered

12. Marketed Cancer Biosimilars Clinical Insight
12.1 Interferon alpha-2a Biosimilar (Inferon™/Inmutag™)
12.2 Interferon alpha-2b Biosimilar(Bioferon™)
12.3 Interferon alpha-2b Biosimilar(Intalfa®)
12.4 Interferon alpha-2b Biosimilar (Laboratorios Varifarma)
12.5 Interferon alpha-2b Biosimilar(ReliFeron®)
12.6 Interleukin-2 Biosimilar(Ilcass)
12.7 Peginterferon alfa-2b (Cylatron®)
12.8 Rituximab Biosimilar(Zytux™)
12.9 Rituximab Biosimilar(Acellbia™)
12.10 Rituximab Biosimilar(Reditux™/Tidecron®)
12.11 Rituximab Biosimilar(Mabtas)
12.12 Rituximab Biosimilar(MabThera®)
12.13 Trastuzumab (Herceptin®)
12.14 Trastuzumab Biosimilar(CANMAb™)
12.15 Filgrastim (Zarxio™)

13. Suspended & Discontinued Cancer Biosimilar Clinical Pipeline
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. Competitive Landscape
14.1 Actavis
14.2 Aequus BioPharma
14.3 Amega Biotech
14.4 Amgen
14.5 API Co. Ltd
14.6 AvesthaGen
14.7 AXXO
14.8 Bio Sidus
14.9 Biocad
14.10 Biocon
14.11 Biogenomics
14.12 BioSavita
14.13 BioXpress Therapeutics
14.14 Boehringer Ingelheim
14.15 Celltrion
14.16 CTI BioPharma
14.17 Dong-A Pharmaceutical
14.18 EPIRUS Biopharmaceuticals
14.19 Fujifilm Kyowa Kirin Biologics
14.20 Gedeon Richter
14.21 Glycotope
14.22 Green Cross
14.23 Harvest Moon Pharmaceuticals
14.24 IBioInc
14.25 Inbiopro Solutions
14.26 Ipca Laboratories
14.27 Lupin
14.28 MAbxience
14.29 Momenta Pharmaceuticals
14.30 Nanogen Biopharmaceutical
14.31 Oncobiologics
14.32 Pfizer
14.33 PharmaPraxis
14.34 PlantForm Corporation
14.35 Reliance Life Sciences
14.36 Samsung Bioepis
14.37 Teva Pharmaceutical
14.38 UMN Pharma
14.39 XBiotech
14.40 Yakult Honsha
14.41 Zydus Cadila

Figure 1-1: Benefits of Cancer Biosimilars
Figure 1-2: Limitations of Cancer Biosimilars
Figure 2-1: Mechanism of Trastuzumab Biosimilar
Figure 2-2: Mechanism of Bevacizumab Biosimilar
Figure 2-3: Mechanism of Cetuximab Biosimilar
Figure 2-4: Mechanism of Filgrastim Biosimilar
Figure 5-1: Global Biosimilars Market (US$ Billion), 2013-2020
Figure 5-2: Global Biosimilar Market by Segment (%), 2020
Figure 5-3: Cancer Biosimilars Pipeline by Phase (%), 2015
Figure 5-4: Cancer Biosimilars Pipeline by Phase (Number), 2015
Figure 5-5: No Development Reported in Cancer Biosimilars Pipeline by Phase (%), 2015
Figure 5-6: No Development Reported in Cancer Biosimilars Pipeline by Phase (Number), 2015
Figure 5-7: Discontinued Cancer Biosimilars in Pipeline by Phase (%), 2015
Figure 5-8: Discontinued Cancer Biosimilars in Pipeline by Phase (Number), 2015
Figure 6-1: Favorable Market Parameters
Figure 6-2: Global Cancer Biosimilars Commercialization Challenges
Figure 14-1: Amgen -Clinical Pipeline
Figure 14-2:Biocon- Clinical Pipeline
Figure 14-3: EPIRUS Biopharmaceuticals- Clinical Pipeline
Figure 14-4: Fujifilm Kyowa Kirin Biologics-Clinical Pipeline
Figure 14-5: Oncobiologics-Clinical Pipeline
Figure 14-6: Zydus Cadila- Clinical Pipeline


Table 1-1: Comparative Analysis between Different Cancers Therapeutic Categories
Table 2-1: Few Trastuzumab Biosimilars
Table 2-2: Few Bevacizumab Biosimilar
Table 2-3: Biosimilar of Cetuximab
Table 2-4: Few Biosimilar Filgrastim Available for Cancer Patients
Table 4-1: Difference between Biosimilars & Small Molecule Drugs
Table 10-1: Samsung Bioepis -Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.